BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6901590)

  • 1. Evidence that an autoantibody of IgG3 subclass against C3b discloses a C3 Nef activity in a pateint with partial lipodystrophy and glomerulonephritis.
    Fontaine M; Daveau M; Lebreton JP; Dumouchel L; Vannier JP; Godin M
    Ann Immunol (Paris); 1980; 131C(1):39-53. PubMed ID: 6901590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of C3 nephritic factor by cultured lymphocytes derived from a patient with partial lipodystrophy.
    Yamada A; Ohi H; Okano K; Watanabe S; Seki M; Hatano M; Koitabashi Y
    J Clin Lab Immunol; 1988 Sep; 27(1):35-7. PubMed ID: 3251045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of nephritic factor as an immunoglobulin.
    Williams DG; Bartlett A; Duffus P
    Clin Exp Immunol; 1978 Sep; 33(3):425-9. PubMed ID: 104814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of activation of the properdin system. Studies on properdin electrophoretic mobility in agarose activation of the alternative pathway.
    Adam C; Williams DG; Peters DK
    Clin Exp Immunol; 1975 Nov; 22(2):240-8. PubMed ID: 813932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The complement abnormalities of lipodystrophy.
    Sissons JG; West RJ; Fallows J; Williams DG; Boucher BJ; Amos N; Peters DK
    N Engl J Med; 1976 Feb; 294(9):461-5. PubMed ID: 1246331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Partial lipodystrophy and glomerulonephritis without complement activation.
    Mery JP; Kourilsky O; Morel-Maroger L; Adam C
    N Engl J Med; 1978 May; 298(18):1034. PubMed ID: 643001
    [No Abstract]   [Full Text] [Related]  

  • 7. Partial lipodystrophy, C3 nephritic factor and clinically inapparent mesangiocapillary glomerulonephritis.
    Bennett WM; Bardana EJ; Wuepper K; Houghton D; Border WA; Götze O; Schreiber R
    Am J Med; 1977 May; 62(5):757-60. PubMed ID: 860726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN.
    Marinozzi MC; Roumenina LT; Chauvet S; Hertig A; Bertrand D; Olagne J; Frimat M; Ulinski T; Deschênes G; Burtey S; Delahousse M; Moulin B; Legendre C; Frémeaux-Bacchi V; Le Quintrec M
    J Am Soc Nephrol; 2017 May; 28(5):1603-1613. PubMed ID: 28096309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation.
    Frémeaux-Bacchi V; Weiss L; Brun P; Kazatchkine MD
    Nephrol Dial Transplant; 1994; 9(7):811-4. PubMed ID: 7970124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulation of the intracellular killing of Staphylococcus aureus by monocytes: regulation by immunoglobulin G and complement components C3/C3b and B/Bb.
    Leijh PC; van den Barselaar MT; Daha MR; van Furth R
    J Immunol; 1982 Jul; 129(1):332-7. PubMed ID: 6979568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
    Schena FP; Pertosa G; Stanziale P; Vox E; Pecoraro C; Andreucci VE
    Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of carbohydrate in the structure and function of nephritic factor.
    Scott DM; Amos N; Bartolotti SR
    Clin Exp Immunol; 1981 Oct; 46(1):120-9. PubMed ID: 6802534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Partial lipodystrophy (cephalothoracic type) with asymptomatic dense deposit disease (author's transl)].
    Houssin A; Saint-André JP; Buzelin F; Guenel J
    Ann Med Interne (Paris); 1981; 132(1):44-7. PubMed ID: 7224470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Partial lipodystrophy with osteomyelitis].
    Böhles H; Kövary PM
    Z Hautkr; 1982 Jan; 57(2):91-100. PubMed ID: 7072309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephritic factor, C3 splitting activity, C3 and factor B breakdown products in glomerular diseases.
    De Vecchi A; Montagnino G; Scalia P; Tarantino A
    Ric Clin Lab; 1980; 10(1):93-7. PubMed ID: 6781054
    [No Abstract]   [Full Text] [Related]  

  • 17. The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase.
    Isenman DE; Podack ER; Cooper NR
    J Immunol; 1980 Jan; 124(1):326-31. PubMed ID: 7350230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disorders of the complement system in lipodystrophy.
    Ipp MM; Minta JO; Gelfand EW
    Clin Immunol Immunopathol; 1977 Mar; 7(2):281-7. PubMed ID: 862255
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined C3b and factor B autoantibodies and MPGN type II.
    Chen Q; Müller D; Rudolph B; Hartmann A; Kuwertz-Bröking E; Wu K; Kirschfink M; Skerka C; Zipfel PF
    N Engl J Med; 2011 Dec; 365(24):2340-2. PubMed ID: 22168663
    [No Abstract]   [Full Text] [Related]  

  • 20. Investigation of the mechanisms of anti-complement activity in Ixodes ricinus ticks.
    Lawrie CH; Sim RB; Nuttall PA
    Mol Immunol; 2005 Jan; 42(1):31-8. PubMed ID: 15488941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.